Novel Biomarkers for Amyotrophic lateral sclerosis (ALS)
- 技術優勢
- Early Detection of ALS, Identify Targets for Drug Therapy, Screening kit for ALS
- 詳細技術說明
- Our inventors have discovered novel biomarkers for ALS detection. A SILAC-based study using ALS fibroblast cells and age-matched control fibroblast cells was performed. SILAC stands for Stable Isotope Labeling by Amino Acids in CellCulture, and is an innovative technique for studying mass spectrometry-based proteomics. Upon data analysis we found 36 proteins that were differentially regulated in ALS fibroblasts compared to normal control cells. Among these proteins, 19 proteins were up-regulated and 17 were down-regulated in ALS compared to control. Based on literature search 26 proteins were foundto be novel. We have validated 3 novel proteins: apolipoprotein B48 (Apo B48), fibulin-1, and Hsp20 based on the availability of reliable antibodies for Western blotting. Validation data confirms that Apo B48 and Hsp20 are down-regulated, and fibulin-1 was found to be up-regulated in ALS fibroblasts in comparison to the normal cells. To our knowledge, there are no current reports of these validated proteins in relation to ALS biomarker use. Overall, our data revealed several novel biomarkers that can be used for development of unique screening kits for ALSdetection and also can be used as novel drug targets.
- *Abstract
-
Researchers at the University of South Florida have discovered novel biomarkers associated with Amytrophic Lateral Sclerosis.
- 國家/地區
- 美國
欲了解更多信息，請點擊 這裡
